This inventor holds 266 USPTO granted patents and 22 published patent applications, plus 5 CIPO patents and 14 EPO patents, primarily in Biopharmaceutical Innovations (CPC class 4353201). Top assignees: Human Genome Sciences, Inc., Smithkline Beecham Corporation, University of Michigan. Active years: 1996-2016.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Inventors with similar research interests:
Location History:
- Odenton, MD (US) (2002)
- Brookevile, MD (US) (2005)
- Brookville, MD (US) (2006)
- Olney, MD (US) (1996 - 2016)
- Brookeville, MD (US) (2003 - 2016)
Company Filing History:
254 out of 676 
7 out of 2,198 
3 out of 3,556 
Years Active: 1996-2016
Areas of Expertise:
Title: Steven M Ruben: Pioneering Innovator in Biomedical Research
Introduction:
In the field of biomedical research and innovative drug development, individuals like Steven M Ruben stand out as true pioneers. With a strong background in life sciences, Ruben has made significant contributions to the field, boasting an impressive portfolio of patents. This article aims to shed light on Ruben's expertise, latest patents, career highlights, and collaborations, showcasing his invaluable contributions to the biomedical and pharmaceutical industries.
Latest Patents:
Ruben's recent patents demonstrate his excellence in harnessing cutting-edge biotechnological techniques for therapeutic purposes. One notable patent is entitled "Vascular endothelial growth factor 2," which focuses on the development and usage of human VEGF-2 antibodies, fragments, and variants. These antibodies hold great promise in preventing, treating, or ameliorating various diseases and disorders. Ruben's patent emphasizes the importance of exploiting the potential of VEGF-2 as a therapeutic target.
Another noteworthy patent by Ruben is titled "Albumin fusion proteins." This invention explores the application of albumin fusion proteins in the treatment, prevention, or amelioration of diseases, disorders, or conditions. Ruben's patent encompasses the nucleic acid molecules encoding these fusion proteins, vectors containing the nucleic acids, host cells transformed with the vectors, and methods for producing albumin fusion proteins. This patent undoubtedly pushes the boundaries of innovative drug development.
Career Highlights:
Ruben's remarkable portfolio of 261 patents speaks volumes about his prowess and commitment to innovation. His extensive involvement with companies like Human Genome Sciences, Inc. underscores his dedication to translating cutting-edge research into practical applications. Ruben's contributions have undoubtedly advanced the field of biomedicine, and his patents provide a solid foundation for further scientific exploration.
Collaborations:
In such a dynamic and collaborative field, Steven M Ruben has had the privilege of collaborating with other esteemed professionals. Notable among his coworkers are Craig A Rosen and Jian Ni, who have undoubtedly contributed to the success of their research efforts. Collaborations foster an environment of knowledge exchange and innovation, enabling scientists like Ruben to reach new heights in their respective fields.
Conclusion:
Steven M Ruben's exceptional career and groundbreaking patents make him a stellar figure in biomedical research and innovation. His expertise in harnessing the potential of therapeutic targets, such as VEGF-2, and leveraging fusion proteins for disease treatment opens up unprecedented possibilities in the field of medicine. As Steven M Ruben continues to push the boundaries of biotechnology, the world eagerly anticipates the future breakthroughs and advancements he will undoubtedly contribute to the scientific community.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile